Important report shows new bivalent booster is a poor inducer of neutralizing antibodies against current strains, i.e., it doesn't work
The vaccine researchers at U Texas Galveston (one of the biggest DOD biodefense contractors) say so. That is big
When UT Galveston says so, and Nature Medicine publishes it, it will not be refuted by the powers that be. Galveston’s vaccine research center even advertises that “vaccine acceptance” is part of its remit. This is a major center for study of emerging infectious diseases and biodefense. Hat tip to Harvey Risch for identifying the article.
Yet as we speak the current administration is spending $475 Million of our money to convince (mostly) the poor and elderly to take it. Why would they do that? Why would they pay doctors $40 per jab—double the usual fee for administering vaccines?
Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine or a BA.5-bivalent booster
Kurhade, C., Zou, J., Xia, H. et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine or a BA.5-bivalent booster. Nat Med (2022).
The newly emerged SARS-CoV-2 Omicron sublineages, including the BA.2-derived BA.2.75.2 and the BA.5-derived BQ.1.1 and XBB.1, have accumulated additional spike mutations that may affect vaccine effectiveness. Here we report neutralizing activities of three human serum panels collected from individuals 23–94 days after dose 4 of a parental mRNA vaccine, 14–32 days after a BA.5-bivalent-booster from individuals with 2–4 previous doses of parental mRNA vaccine, or 15–32 days after a BA.5-bivalent-booster from individuals with previous SARS-CoV-2 infection and 2–4 doses of parental mRNA vaccine. The results showed that a BA.5-bivalent-booster elicited a high neutralizing titer against BA.4/5 measured at 14- to 32-day post-boost; however, the BA.5-bivalent-booster did not produce robust neutralization against the newly emerged BA.2.75.2, BQ.1.1, or XBB.1. Previous infection significantly enhanced the magnitude and breadth of BA.5-bivalent-booster-elicited neutralization. Our data support a vaccine update strategy that future boosters should match newly emerged circulating SARS-CoV-2 variants.